Pro-Gly-Pro raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
=== South Korea === The crisis has not had a dramatic impact on the lives of most South Koreans, and energy minister Kim Sung-hwan has said that the country would not experience problems with supply for over a year. However, the Korean Government launched an energy-saving campaign, encouraging its citizens to have brief showers, and limit their use of washing machines, and it has postponed the decommissioning of coal-fired power plants as well as reducing the limit on electricity made from coal.
During the 1990s the National Arts Council was created to spearhead the development of performing arts, along with visual and literary art forms. The National Gallery Singapore is the nation's flagship museum with some 8,000 works from Singaporean and other Southeast Asian artists. The Singapore Art Museum focuses on contemporary art from a Southeast Asian perspective. The Red Dot Design Museum celebrates exceptional art and design of objects for everyday life, hosting more than 1,000 items from 50 countries. The lotus-shaped ArtScience Museum hosts touring exhibitions that combine art with the sciences. Other major museums include the Asian Civilisations Museum, the Peranakan Museum, and The Arts House. The Esplanade is Singapore's largest performing arts centre. In 2016 alone, it was the site of 5,900 free art and culture events. Literature of Singapore, or "SingLit", consists of a collection of literary works by Singaporeans written chiefly in the country's four official languages: English, Malay, Mandarin, and Tamil. Singapore is increasingly regarded as having four sub-literatures instead of one. Many significant works have been translated and showcased in publications such as the literary journal Singa, published in the 1980s and 1990s with editors including Edwin Thumboo and Koh Buck Song, as well as in multilingual anthologies such as Rhythms: A Singaporean Millennial Anthology Of Poetry (2000), in which the poems were all translated three times each.
Paliperidone palmitate (PP), sold under the brand names Invega Sustenna, Xeplion, Shansida (Chinese: 善思达), Erzofri and Psokadron for the once‑monthly formulation, and as Invega Trinza/Trevicta (three‑monthly) and Invega Hafyera/Byannli (six‑monthly), is a long-acting injectable atypical antipsychotic of the benzisoxazole class, used in the treatment of schizophrenia and schizoaffective disorder. The original product was developed by Janssen Pharmaceuticals, Inc. (Johnson & Johnson), which continues to manufacture most of the branded versions worldwide. It is an antipsychotic ester – specifically the palmitate ester of paliperidone – and acts as a long-lasting form of paliperidone. Paliperidone palmitate is formulated as an aqueous suspension, has a strong smell similar to alcohol, and is administered by intramuscular injection into deltoid or gluteal muscle once every 1, 3, or 6 months depending on the formulation. A formulation for injection once every 6 months is also pending regulatory approval as of September 2021.
=== Cholesterol clearance === Synthetic platelets are being explored for their potential in cholesterol clearance by facilitating the targeted removal of cholesterol from the bloodstream, offering a novel approach to treating hypercholesterolemia and preventing cardiovascular diseases. Elevated low-density lipoprotein cholesterol (LDL-C) is a key contributor to coronary heart disease, largely regulated by the interaction between LDL receptors (LDLR) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Since PCSK9 reduces LDLR availability, inhibiting it can enhance LDL-C clearance. To explore this, researchers designed platelet-mimicking nanoparticles to deliver siRNA targeting Pcsk9. These nanoparticles effectively lowered Pcsk9 mRNA levels by 66% in cell studies and reduced plasma LDL-C by 28% in animal models, without significantly altering high-density lipoprotein cholesterol (HDL-C) or triglycerides (TGs). This strategy demonstrates the potential of biomimetic nanoparticles for RNA-based therapies aimed at treating high cholesterol.
20–30, 1991 Salgues, E., "Naram-Sin's conquests of Subartu and Armanum", Akkade is King. A collection of papers by friends and colleagues presented to Aage Westenholz on the occasion of his 70th birthday 15 May 2009, hrsg. v. Gojko Barjamovic (Uitgaven van het Nederlands Instituut voor het Nabije Oosten te Leiden 118), pp. 253–272, 2011 Steinkeller, Piotr, "The Roundlet of Naram-Suen", History, Texts and Art in Early Babylonia: Three Essays, Berlin, Boston: De Gruyter, pp. 158–164, 2017 F.Thureau-Dangin, Une inscription de Naram-Sin", Revue d’Assyriologie et d’archéologie Orientale, vol. 8, no. 4, pp. 199–200, 1911
Sources: en.wikipedia.org
March 31, 2004: The Ministry Delegate for Parity and Professional Equality gains its autonomy. May 26, 2004: Law concerning divorce; the protection of the spouse victim of violence is taken into account. July 1, 2004: Decree concerning the conditions for performing voluntary terminations of pregnancy outside healthcare establishments and amending the Public Health Code (second part: Regulatory part). August 6, 2004: Law concerning bioethics. November 24, 2004: Plan to combat violence against women. November 24, 2004: Ordinance concerning the legislative part of the Code on the Entry and Residence of Foreigners and the Right of Asylum. March 23, 2006: Law concerning equal pay between women and men. April 5, 2006: Law on strengthening the prevention and repression of violence within couples or against minors. December 30, 2004: Law establishing the French Equal Opportunities and Anti-Discrimination Commission (HALDE). March 17, 2005: Decree concerning the family reunification of foreigners for the application of Book IV of the Code on the Entry and Residence of Foreigners and the Right of Asylum. April 2, 2005: Orientation and Program Law for the Future of the School, which emphasizes that it must "promote coeducation and equality between men and women." June 2, 2005: Creation of the Ministry Delegate for Social Cohesion and Parity. July 4, 2005: Ordinance reforming filiation. August 2, 2005: Law in favor of small and medium-sized enterprises; it notably includes provisions concerning the status of the collaborating spouse.
===== Cuba ===== On 15 September, Lula and four of his cabinet minister visited Cuba where they met with Cuban president and first secretary of the Communist Party of Cuba Miguel Díaz-Canel. During his visit, Lula also attended a summit of the Group of 77 plus China in Havana where he lamented the United States embargo against Cuba stating that the island "is the victim of an illegal economic embargo, Brazil is against any unilateral coercive measure". Lula also criticized the inclusion of Cuba in the US list of states sponsors of terrorism.
=== Discontinued === ABT-436 – vasopressin V1b receptor antagonist – alcoholism Adrogolide (ABT-431; DAS-431) – dopamine D1 receptor agonist – cocaine-related disorders ADX-629 – aldehyde inhibitor / reactive aldehyde species (RASP) inhibitor – alcoholism, alcoholic hepatitis ADX-10061 (CEE-310; CEE-03-310; NNC-010687; NNC-687) – dopamine D1 receptor antagonist – smoking withdrawal, substance-related disorders ADX-71441 – GABAB receptor positive allosteric modulator – alcoholism, cocaine-related disorders, substance-related disorders Anatabine (RCP-006) – nicotinic acetylcholine receptor agonist – smoking withdrawal ANS-6637 (GS-6637; GS-6673) – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism, opioid-related disorders, smoking withdrawal, substance-related disorders Arbaclofen placarbil (R-baclofen placarbil; XP-19986) – GABAB receptor agonist – alcoholism ASP-8062 – GABAB receptor modulator – opioid-related disorders Aticaprant (AVTX-501; CERC-501; JNJ-3964; JNJ-67953964; JNJ-67953964-AAA; LY-2456302) – κ-opioid receptor antagonist – alcoholism, cocaine-related disorders, smoking withdrawal Azasetron (nazasetron; Serotone; Y-25130) – serotonin 5-HT3 receptor antagonist – cocaine-related disorders AZD-4041 – orexin OX1 receptor antagonist – smoking withdrawal Baclofen/samidorphan (ALKS-29; ALKS-33/baclofen; baclofen/ALKS-33) – combination of baclofen (GABAB receptor agonist) and samidorphan (μ-opioid receptor antagonist) – alcoholism Befloxatone (MD-370503) – monoamine oxidase A (MAO-A) inhibitor – smoking withdrawal BP-897 – dopamine D3 receptor agonist – cocaine-related disorders BR-9003 (BR-9003A) – undefined mechanism of action – smoking withdrawal BTRX-246040 (LY-2940094) – nociceptin receptor agonist – alcoholism Buprenorphine/naloxone (NanoBUP; NTC-0510; NTC-510) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Buprenorphine/samidorphan (ALKS 33-BUP; ALKS 33/buprenorphine; ALKS-5461; BUP-ALKS 33; buprenorphine/ALKS-33; buprenorphine/RDC 0313; RDC 0313/buprenorphine; samidorphan/buprenorphine) – combination of buprenorphine (non-selective opioid receptor modulator) and samidorphan (μ-opioid receptor antagonist) – cocaine-related disorders Cannabidiol (CBD; synthetic cannabidiol; RAD-011) – cannabinoid/various actions – substance-related disorders CVL-936 – dopamine D2 and D3 receptor antagonist – substance-related disorders CX-1739 – AMPA receptor positive allosteric modulator (ampakine) – substance-related disorders Deudimethyltryptamine (HLP004; HLP-004; CYB004; CYB-004; DMT-d10; deuterated dimethyltryptamine; dDMT) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – substance-related disorders Deupsilocin (HLP003; HLP-003; CYB003; CYB-003; psilocin-d10; deuterated psilocin) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism Dianicline (SSR-591813) – nicotinic acetylcholine receptor agonist – smoking withdrawal Drinabant (AVE-1625; INDV-5004; OPNT-004) – cannabinoid CB1 receptor antagonist – substance-related disorders Ecopipam (EBS-101; PSYRX-101; SCH-39166) – dopamine D1 receptor antagonist – cocaine-related disorders Eglumetad (eglumegad; LY-354740) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist – smoking withdrawal Elinzanetant (BAY-3427080; GSK-1144814A; GSK-1144814; Lynkuet; NT-814) – neurokinin NK1 and NK3 receptor antagonist – opioid-related disorders Femoxetine (femoxitine; FG-4963; Malexil; NNC-204963) – selective serotonin reuptake inhibitor (SSRI) – alcoholism Gabapentin enacarbil (ASP8825; Gabapentin-XP; GSK-1838262; Horizant; Regnite; Solzira; XP13512) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel blocker) – alcoholism Gepirone (Ariza; BMY-13805; Exxua; MJ-13805; Org-33062; TGFK07AD; Travivo; Variza) – serotonin 5-HT1A receptor agonist – cocaine-related disorders Istradefylline (KW-6002; Nourianz; Nouriast) – adenosine A2 receptor antagonist ITI-333 – serotonin 5-HT2A receptor antagonist, dopamine D1 receptor antagonist, α1A-adrenergic receptor antagonist, μ-opioid receptor partial agonist – substance-related disorders JNJ-39393406 – α7 subunit-containing nicotinic acetylcholine receptor positive allosteric modulator – smoking withdrawal JZP-150 – fatty acid amide hydrolase (FAAH) inhibitor – alcoholism Lisdexamfetamine (LDX; Elvanse; NRP-104; S-877489; SHP-489; SPD-489; Tyvense; Venvanse; Vyvanse) – norepinephrine–dopamine releasing agent (NDRA) – cocaine-related disorders Lorcaserin (APD-356; Belviq; E2023; Venespri) – serotonin 5-HT2C receptor agonist – smoking withdrawal Manifaxine (BW-1555U88; GW-320659) – norepinephrine–dopamine reuptake inhibitor (NDRI) – smoking withdrawal Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – smoking withdrawal Nalmefene (CPH-101; JF-1; Lu AA36143; Nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – smoking withdrawal Nepicastat oral (APL-1401; SYN-117) – dopamine β-hydroxylase (DBH) inhibitor – cocaine-related disorders Neramexane (KRP-209; MRZ-2/579) – NMDA receptor antagonist, nicotinic acetylcholine receptor antagonist – alcoholism NIC-002 (NIC002; CYT002-NicQβ; Nicotine-Qβ) – immunostimulant (nicotine vaccine) – smoking withdrawal NicVAX – immunostimulant (nicotine vaccine) – smoking withdrawal Nornicotine – nicotinic acetylcholine receptor agonist – smoking withdrawal NS-2359 (GSK-372475) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – alcoholism NYX-783 – ionotropic glutamate NMDA receptor modulator – alcoholism, opioid-related disorders OREX-1019 – μ-opioid receptor agonist, δ-opioid receptor antagonist, κ-opioid receptor antagonist, nociceptin receptor agonist – cocaine-related disorders OREX-1038 – μ-opioid receptor agonist – cocaine-related disorders, opioid-related disorders Oxytocin intranasal (Syntocinon Nasal Spray; TUR-001) – oxytocin receptor agonist – alcoholism Quetiapine (FK-949; FK949E; ICI-204636; Seroquel) – atypical antipsychotic (non-selective monoamine receptor modulator) – alcoholism Rimonabant (Acomplia; SR-141716; SR-141716A; Zimulti) – cannabinoid CB1 receptor antagonist – smoking withdrawal Risperidone (JNJ-410397-AAA; R-64766; R064766; Risperdal; Risperdal Consta; Risperdal Depot) – atypical antipsychotic (non-selective monoamine receptor modulator) – substance-related disorders RTI-113 – dopamine reuptake inhibitor (DRI) (cocaine analogue) – cocaine-related disorders Samidorphan (ALKS-33; RDC-0313; RDC-0313-00) – μ-opioid receptor antagonist – alcoholism, substance-related disorders Sembragiline (EVT-302; RG-1577; RO-4602522) – monoamine oxidase B (MAO-B) inhibitor – smoking withdrawal Serlopitant (JTS-661; MK-0594; VPD-737) – neurokinin NK1 receptor antagonist – alcoholism Surinabant (SR-147778; SR147778) – cannabinoid CB1 receptor antagonist – alcoholism, smoking withdrawal TA-NIC – immunostimulant (nicotine vaccine) – smoking withdrawal Tradipitant (LY-686017; Nereus; VLY-686) – neurokinin NK1 receptor antagonist – alcoholism Verucerfont (GSK-561679; NBI-77860) – corticotropin-releasing factor 1 (CRF1) receptor antagonist Vigabatrin (γ-vinyl-GABA; gamma-vinyl-GABA; GVG; M071754; MDL-71754; RMI-71754; Sabril; Sabrilex) – GABA transaminase (GABA-T) inhibitor – cocaine-related disorders, substance-related disorders
==== Elimination ==== Muscimol is excreted by the kidneys into urine. It is excreted partially unmetabolized. This has been taken advantage of by Siberian practitioners of the traditional entheogenic use of Amanita muscaria via recycling of muscimol in urine. The elimination half-life of muscimol in humans is unknown. The closely related drug gaboxadol (THIP), which is a cyclized derivative of muscimol, has an elimination half-life in humans of 1.5 to 2 hours. In rodents, the half-life of gaboxadol was about twice as long as that of muscimol. Gaboxadol is said to be more resistant to metabolism than muscimol, for instance not being a substrate for GABA-T. Despite the preceding findings however, gaboxadol is shorter-lasting in its effects than muscimol in rats, with durations of up to 3 hours and more than 5 hours, respectively.
Sources: en.wikipedia.org
==== Estonia ==== In April 2007, Estonia came under cyber attack in the wake of relocation of the Bronze Soldier of Tallinn. The largest part of the attacks were coming from Russia and from official servers of the authorities of Russia. In the attack, ministries, banks, and media were targeted. This attack on Estonia, a seemingly small Baltic state, was so effective because of how most of Estonian government services are run online. Estonia has implemented an e-government, where banking services, political elections, taxes, and other components of a modern society are now all done online.
The cause of Fukuyama congenital muscular dystrophy is rooted in the FKTN gene, located at human chromosome 9q31, encoding the protein fukutin. Mutations in this gene, and therefore the fukutin protein, are the cause of FCMD. The disease is inherited in an autosomal recessive manner. This means the defective gene responsible for the disorder is located on an autosome (chromosome 9 is an autosome), and two copies of the defective gene (one inherited from each parent) are required in order to be born with the disorder. The parents of an individual with an autosomal recessive disorder both carry one copy of the defective gene but usually do not experience any signs or symptoms of the disorder. Two mutations have been identified. The first and most common is an SVA retrotransposal insertion in the 3'-untranslated region. The second is a deep-intronic point mutation c.647+2084G>T. This second mutation has only been found to date in the presence of the first mutation.
In 2011, the United States Environmental Protection Agency introduced the gallon gasoline equivalent as a unit of energy because their research showed most U.S. citizens do not understand the standard units. The gallon gasoline equivalent is defined as 33.7 kWh, or about 1.213×108 joules. Energy efficiency of electric and alternative-fuel vehicles can be given as miles per gallon gasoline equivalent.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.